Incentives built into the new Medicare Part D drug plan to increase the use of generic drugs are driving down program costs significantly, according to the results of a new study. Researchers at Verispan found that 55% of all prescriptions being filled by Medicare patients during the first 3 months of the new program were for generic drugs.
Teva Pharmaceuticals was the leading supplier of drugs for Medicare recipients enrolled in Part D. Four other generic manufacturersMylan Pharmaceuticals, Watson Pharmaceuticals Inc, IVAX Pharmaceuticals Inc, and Mallinckrodt Medicalalso ranked among the top 10, the researchers said.
One study linked multiple pregnancies to an increased risk of developing atrial fibrillation later in life, and another investigated the association between premature delivery and cardiovascular disease.
Clinical features with downloadable PDFs